3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

Grail's revenue rose from $93 million in 2023 to $147 million in 2025, while Galleri test volume increased 42% year over year to more than 117,000 tests in the first half of 2026. An FDA panel voted affirmatively on Galleri's safety, efficacy and benefit-risk profile, supporting a potential premarket approval in 2027 that could unlock Medicare and private-insurance reimbursement. Analysts forecast 25% revenue CAGR from 2025 to 2028 to $286 million, though Grail's $6.1 billion market capitalization already values it at roughly 21x projected 2028 sales and approval remains the key risk.

Analysis

GRAL’s valuation is no longer anchored to its current direct-pay business; it embeds meaningful probability of broad reimbursement and therefore leaves little room for another clinical-utility disappointment. The decisive issue is not analytical safety or cancer-signal detection, but whether prospective evidence demonstrates that earlier detection changes treatment pathways and mortality at an acceptable false-positive/workup burden. That distinction matters because commercial payers can delay coverage even after approval, making a 2027 regulatory event a potential trading catalyst rather than an immediate revenue inflection.

Near term, momentum can persist as investors re-rate the probability of approval, but the next 1-3 months are vulnerable to profit-taking because the evidence base remains contested after the NHS result. Over 6-18 months, reimbursement coding, Medicare coverage posture, and employer-program renewal rates will matter more than test-volume growth: covered adoption requires physicians to order the test repeatedly and health systems to absorb downstream imaging, biopsies, and navigation costs. A high false-positive burden would shift economic value toward diagnostic imaging and oncology workups while undermining payer willingness to reimburse GRAL.

The contrarian view is that approval may be substantially less valuable than consensus assumes. A premium multiple on revenue that is still largely self-pay can compress sharply if FDA labeling is narrow, insurers classify multicancer early detection as investigational, or cash burn requires incremental financing before coverage scales. Conversely, a favorable label plus an early Medicare coverage pathway would invalidate the cautious case and could create a revenue-estimate reset well before actual claims volume appears.

Key Decisions for Investors

• Do not chase GRAL common stock into regulatory optimism; maintain a watchlist entry only after a 20-30% pullback or after confirmation of FDA label scope and post-approval evidence requirements. The thesis is falsified positively by a broad label coupled with a credible Medicare coverage pathway.
• For event exposure, use defined-risk GRAL call spreads dated 6-12 months beyond the expected FDA decision, only if listed-option liquidity and implied volatility permit. Size as a binary biotech event: upside requires approval plus reimbursement optimism, while maximum loss is premium paid.
• Monitor quarterly cash burn, test repurchase/renewal rates, and payer contracts rather than headline test volumes. A rising volume trend without improving gross margin or covered lives is a warning that adoption remains subsidy-driven and argues for avoiding the equity.
• Consider ILMN only as a separate capital-allocation and core-sequencing turnaround thesis, not as a clean GRAL proxy. Any residual ownership or distribution-related exposure can create technical correlation, but GRAL’s regulatory outcome should not be used to underwrite ILMN earnings.